AURORA is a clinical research study designed to explore an investigational drug—maribavir—in hematopoietic stem cell transplant (HSCT) recipients with a CMV infection that is not showing symptoms (is asymptomatic).
The main goal of the 22-week study is to see if maribavir works to clear CMV infections from the blood in HSCT recipients with an asymptomatic CMV infection. Participants will be randomized to receive either maribavir (the investigational drug) or valganciclovir for 8 weeks. Valganciclovir is an anti-CMV treatment that is most often used as a first-line treatment for CMV infection. The study doctor or staff will then assess participants for an additional 12 weeks after treatment, to evaluate if they remain free of CMV infection (no virus detected in blood). The study drugs are given as an oral pill.